Podcasts about Lymphoma

Heather Brooker hosts your Friday morning Wake Up Call. Former counterterrorism coordinator for DHS and current ABC News consultant John Cohen opens the show talking about political violence and why it's a ‘both sides' problem. The House Whisperer Dean Sharp joins the show to talk about proposed ‘zero zero' rules and why they are becoming a hot topic in California. Bloomberg Media's Courtney Donohoe shares the latest in business and Wall Street.

Millions of Americans are part of the Sandwich Generation, people who are raising children while also caring for aging parents. For KFI's Heather Brooker, that role became deeply personal when her mother, Barbara, faced lymphoma not once, but twice. For National Blood Cancer Awareness Month, Heather shares her family's story of cancer survival, resilience, and the everyday challenges of balancing life in the middle. With insights from a City of Hope oncologist and a family therapist, this conversation sheds light on the stress, strength, and hope that define the Sandwich Generation.

In this episode of Everyday Oral Surgery, we continue our Heme Series on all things blood-related by discussing lymphomas and multiple myeloma. Joining Dr. Stucki on the podcast again, to share a wealth of knowledge, are Drs. Andrew Jenzer and Maxwell Lloyd. They delve into a discussion on the basics of lymphomas, dissecting the two categories of Hodgkin's and non-Hodgkin lymphoma, and get into the diagnosis and presenting symptoms, stages, risk stratification, and treatments of each category. Next, they touch on what Tumor Lysis Syndrome (TLS) is and dive into a broad discussion on multiple myeloma. Dr. Lloyd breaks down the spectrum of this disease, including the signs and symptoms, testing and diagnostics, and explains that there is no cure for the disease. He also expands on the various treatments and management regimens available. To hear more, including thoughts on how to improve communication between collaborating teams, be sure not to miss out on today's episode. Thanks for tuning in!Key Points From This Episode:Introduction to today's topic as we continue our Heme Series.Dr. Lloyd talks us through lymphoma basics.Dr. Jenzer unpacks the presenting symptoms of the Hodgkin lymphoma category.Stages and risk stratification that constantly evolve: Ann Arbor Staging System. Treatment of lymphoma: thinking broadly, as regimens seem to be changing quickly.  We discuss the same aspects, but of the non-Hodgkin lymphoma category.Dr. Lloyd dives broadly into the chemotherapy regimen options for non-Hodgkin lymphoma.He explains a double-hit lymphoma and the associated treatment.We discuss Tumor Lysis Syndrome (TLS).Dr. Jenzer explains what multiple myelomas are. Dr. Lloyd further unpacks the spectrum of this disease (multiple myeloma).Signs and symptoms of multiple myeloma.An explanation for the lack of a cure for multiple myeloma.Testing and diagnostics of multiple myelomaDr. Lloyd broadly delves into the different types of medications and treatments used in managing multiple myeloma.He touches on some of the side effects of the medications.Big takeaway points from today's discussion.Dr. Lloyd's thoughts on how we can improve communication between collaborating teams.Final thoughts and recommendations to listeners.Links Mentioned in Today's Episode:Dr. Andrew Jenzer Email — andrew.jenzer@duke.edu Dr. Maxwell Lloyd — https://connects.catalyst.harvard.edu/Profiles/display/Person/192727 AAOMS — https://aaoms.org/education-meetings/meetings/ NCCN Guidelines — https://www.nccn.org/guidelines/category_1 Ann Arbor Staging System — https://www.ncbi.nlm.nih.gov/books/NBK65726.23/table/CDR0000062933__557/?report=objectonly St. Louis Course — https://stlomfsreview.com/ Everyday Oral Surgery Website — https://www.everydayoralsurgery.com/ Everyday Oral Surgery on Instagram — https://www.instagram.com/everydayoralsurgery/ Everyday Oral Surgery on Facebook — https://www.facebook.com/EverydayOralSurgery/Dr. Grant Stucki Email — grantstucki@gmail.comDr. Grant Stucki Phone — 720-441-6059

Today, on World Lymphoma Awareness Day, Professors Yok Lam Kwong, Wee Joo Chng, and Eric Tse join us in this joint episode of The Lancet Haematology and The Lancet Regional Health - Western Pacific to discuss their recent Series on advances in genomic techniques that have transformed the diagnosis, prognosis, and targeted treatment of mature T-cell and natural killer-cell lymphoma.Read the Series:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00228-5/?dgcid=buzzsprout_icw_podcast_September_25_lanhaeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this week's episode we'll learn about persistent changes in immune profiles in patients who have had diffuse large B-cell lymphoma, or DLBCL, and other cancers; that plasminogen activation and plasmin activity do not appear to play a role in routine physiological prevention of venous thromboembolism, or VTE; and about a novel mechanism that makes hematological malignancies carrying epigenetic mutations susceptible to PARP inhibitors.Featured Articles:Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatmentPlasminogen activation and plasmin activity are not required to prevent venous thrombosis/thromboembolismTransposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

Mycosis fungoides - a term that is both misleading and redundant. It represents just one aspect of the often complex world of cutaneous T-cell lymphoma. When should clinicians suspect cutaneous T-cell lymphoma? How is it accurately diagnosed? What treatment options are available? In this episode, dermatologists Dr Friyana Bhabha and A/Prof Aaron Robinson provide expert insights into these questions.See omnystudio.com/listener for privacy information.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD CAR T-cell therapies have helped transform the treatment of aggressive lymphomas, but could they also change the game for slower-growing, harder-to-treat diseases like marginal zone lymphoma? Based on new data from the TRANSCEND FL study, liso-cel achieved a 95 percent overall response rate and sustained 24-month progression-free survival in relapsed/refractory marginal zone lymphoma. Here with Dr. Charles Turck to share the key efficacy and safety findings is Dr. Sairah Ahmed, Professor in the Department of Lymphoma and Myeloma and CAR T Program Director at MD Anderson Cancer Center.

Dr Rebecca Leon and Dr Sarah Taylor are joined by Dr Suzanne Roberts, Consultant Haematologist at Bolton NHS Foundation Trust and Clinical Lead for Haemato-oncology at GM Cancer Alliance, to discuss the diagnosis of leukaemia and lymphoma in primary care. They cover common presentations, such as persistent lumps, overwhelming tiredness, and unexplained itching, as well as rare symptoms like facial swelling. The episode explores key investigations, when to be concerned about blood tests, practical advice on referrals, and important differences between acute and chronic leukaemias. Plus, the importance of vigilance, safety netting and advice for monitoring patients with possible haematological cancers.If you loved this episode and would like to hear more like this, please send your review to the-christie.gatewayc@nhs.net and share the series with a colleague.GPs Talk Cancer is the podcast series from GatewayC. GatewayC is the free early cancer diagnosis resource funded by the NHS and is part of The Christie NHS Foundation Trust. View the full shownotes for this episode at Podcast - GatewayCProduced by Louise Harbord from GatewayC and Listening Dog Media.DISCLAIMER: We know this podcast might be of interest to anybody, however it is aimed at primary care health professionals. All patient cases are based on real stories from our clinical practice as GPs. They are fully anonymised with no identifiable patient data. All featured statistics are accurate at the time of recording. All views expressed by guest speakers are their own. Hosted on Acast. See acast.com/privacy for more information.

In this podcast Nancy and Stewart share their personal blood cancer experiences as LGBTQIA+ people. They describe the additional challenges they faced, and are faced by others, due to gender and/or sexual identity. The need to continuously come out, explain your relationship to those around you and not feeling safe in the healthcare space.  Stewart tells us about why he set up the charity OUTpatients and how they seek to support LGBT+ people with cancer and after treatment. They agree that having cancer is hard for everyone, but that it should not be harder for LGBT+ people.Lymphoma Voices is a series of podcasts for people living with lymphoma, and their family and friends. In each podcast, we are in conversation with an expert in their field, or someone who has been personally affected by lymphoma, who shares their thoughts and experiences.   Lymphoma Action is the only charity in the UK dedicated to supporting people affected by lymphoma. We are here to make sure that everyone affected by the condition receives the best possible information, support, treatment and care. Our services include a Freephone helpline, support group network, Buddy Service, medical information, conferences for those affected by lymphoma, and education and training for healthcare professionals. We would like to thank all of our incredible supporters whose generous donations enable us to offer all our essential support services free of charge. As an organisation we do not receive any government or NHS funding and so every penny received is truly valued. From everyone at Lymphoma Action and on behalf of those affected by lymphoma, thank you. For further information visit: www.lymphoma-action.org.uk 

In this week's episode, we'll learn about how TET2 is often mutated in myeloid malignancies and clonal hematopoiesis. In new work, expansion of Tet2-mutant HSPCs was dependent on Ncoa4, the cargo receptor mediating ferritinophagy. We'll iron out the implications. After that: a double-oh-seven license to kill in T-cell leukemia/lymphoma. WU-CART-007 is an off-the-shelf CAR T product with manageable safety and encouraging efficacy. With further work, it could become a new option for patients in urgent need of therapy. Finally: a comprehensive genetic study of classical Hodgkin lymphoma using circulating tumor DNA. This new research provides novel and complex insights on genetic subtypes, prognostic biomarkers, neoantigens in the disease environment, and more.Featured Articles:An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4-mediated ferritinophagy as a dependence in Tet2-deficient hematopoiesisPhase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesA comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA

In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently under development for multiple myeloma.LymphomasDLBCL: Real-world outcomes post axi-cel, CAR T vs autologous HSCTFL: Tisa-cel (ELARA), axi-cel (ZUMA-5)MZL: Liso-cel (TRANSCEND FL)MCL: Real-world outcomes post brexu-celCLL: Liso-cel (TRANSCEND CLL 004)Multiple MyelomaCilta-cel (CARTITUDE-1)Anito-cel (iMMagine-1)GC012FArlo-celBMS-986453TriPRIL Presenters:Brad Kahl, MDProfessor of MedicineWashington University St Louis, MissouriNoopur Raje, MD Director, Center for Multiple MyelomaMassachusetts General Hospital Cancer CenterProfessor of MedicineHarvard Medical SchoolBoston, Massachusetts Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.Link to full program: https://bit.ly/3ViR62V

To the people who read her blog and attended her church, Amanda C. Riley was a beautiful, young wife and mother who managed to live her life with hope and faith even as she was dying of Hodgkin's Lymphoma. But who was the real Amanda?  The story of how this beguiling woman deceived and betrayed countless supporters, including many of her closest friends, is so compelling, Charlie Webster's 2023 “Scamanda” was the most downloaded and shared podcast, world-wide, on Apple that year, since sparking a 2025 Hulu docuseries. In Part 1 of this fascinating podcast, we first introduce you to the carefully-crafted persona Amanda showed to the world, then take you behind the scenes to meet the real Amanda C. Riley. Join us as we walk through the events that led to one of the most infamous and morally unethical scams ever documented… and ultimately resulted in a first-ever case of its kind for the FBI.  Listen (and follow!) on your favorite app or Scandal Water Podcast YouTube channel.  Thank you to listener Rebekah for her ongoing support on Buymeacoffee.com!   How to support Scandal Water: Rate, review and subscribe! Send your shoutouts to scandalwaterpodcast@gmail.com. Become a member on patreon.com/ScandalWaterPodcast or buymeacoffee.com/scandalwaterpod – which will also grant you access to fabulous bonus content! #Scamanda #Scam #ScammySeptember #TeamAmanda #AmandaCRiley #HodgkinsLymphoma CharlieWebster #Podcaster #Podcast #HuluDocumentary #Season5 #ScandalWaterPodcast 

Blood Editor, Dr. Thomas Coates interviews Dr. Emanuele Angelucci on his paper, "How I manage iron overload in the hematopoietic cell transplantation setting" which is featured in Blood's "How I Treat Series on Iron Overload in Hematologic Disorders". See the full How I Treat series in volume 145 issue 4 of Blood. 

In this week's episode we'll learn about targeting NPM1 in acute myeloid leukemia. Researchers report the first clinical evidence of a menin inhibitor inducing complete remissions in AML with a NPM1 mutation. This validates NPM1 as a new therapeutic target in AML, alongside FLT3, IDH1/2, and KMT2A. Also on the podcast: targeting CD137 to prevent graft-versus-host disease. In nonhuman primates, a single dose of a CD137 antibody-drug conjugate provided long-term protection, with one important caveat: the potential for viral reactivation.Featured Articles: Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyA single dose of a CD137 antibody–drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Forat Lutfi, MD Guest: Nilanjan Ghosh, MD, PhD For patients with relapsed/refractory large B-cell lymphoma, timely access to CAR T-cell therapy can be life-saving, but communication gaps between referring physicians and CAR T centers can lead to delays or missed opportunities. Fortunately, practical strategies like building strong referral networks, improving direct communication, and aligning on shared care responsibilities can streamline access and improve outcomes. Joining Dr. Charles Turck to share their insights on how we can bridge these communication gaps are Drs. Forat Lutfi and Nilanjan Ghosh. Dr. Lutfi is an Assistant Professor of Hematologic Malignancies and Cellular Therapeutics at University of Kansas Medical Center, and Dr. Ghosh is a Professor of Cancer Medicine at the Wake Forest University School of Medicine in Charlotte, North Carolina.

In this week's episode we'll learn about how by combining PET response with circulating tumor DNA, or  ctDNA, in newly treated patients with follicular lymphoma, investigators identify those patients likely to progress within 24 months of initial treatment, also known as POD24. After that: Immune hotspots in aplastic anemia. These newly identified hotspots potentially represent sites in the bone marrow where the active immune response takes place, driving the destruction of hematopoietic stem and progenitor cells. Finally, allogeneic transplantation for Hodgkin lymphoma in the checkpoint inhibitor era. In a large, retrospective study, patients with prior checkpoint inhibitor exposure had remarkable outcomes, particularly when post-transplant cyclophosphamide was used.Featured Articles: Combined PET and ctDNA response as predictors of POD24 for follicular lymphoma after first-line induction treatmentImaging Mass Cytometry Reveals the Order of Events in the Pathogenesis of Immune-Mediated Aplastic AnemiaOutcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis

In this episode of Blood Cancer Talks, we have Dr. Adrian Minson from the Peter MacCallum Cancer Centre to discuss the latest developments in lymphoma presented at the recent EHA and ICML meetings in June 2025. The episode focuses primarily on the emerging role of bispecific antibodies in various combinations and treatment settings for diffuse large B-cell lymphoma (DLBCL).Key Clinical Trials Discussed1. POLARGO Trial - Polatuzumab + R-GemOx vs R-GemOx in R/R DLBCL2. SUNMO Trial - Mosunetuzumab + Polatuzumab vs R-GemOx in R/R DLBCL3. STARGLO Trial - Glofitamab + GemOx vs R-GemOx in R/R DLBCL (2-Year Update)4. EPCORE NHL-5 & NHL-7 - Epcoritamab Combinations in Frontline DLBCL5. EPCOR-RICE - Epcoritamab + R-ICE in Transplant-Eligible R/R DLBCL6. LOTIS-7 Trial - Loncastuximab + Glofitamab in R/R DLBCL7. Additional Studies Mentioned:R-Pola-Glo Frail StudyDLBCL Classification

In this week's episode, we'll learn more about how exogenous CD19 stimulation affects CAR T-cell persistence in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy; new algorithms that incorporate sequential rapid immune-assays, intended to improve diagnosis of heparin-induced thrombocytopenia, and resource-adaptive survival prediction models to help guide management of patients with chronic myelomonocytic leukemia.Featured Articles:Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALLSequential combinations of rapid immunoassays for prompt recognition of heparin-induced thrombocytopeniaBLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

Today's guest is Rebecca Thomas, also known as "Giddy Up" within her cancer community, due to her love of horses and her inspiring journey. Rebecca was diagnosed with Hodgkin's Lymphoma at age 18 and has been a survivor for 33 years now, including a breast cancer diagnosis in 2019. She embodies living a meaningful, vibrant life as a long term survivor.We talk about how diagnosis as a young adult shapes the rest of your life, the wonder of the human body and what it can do, the healing power of horses, the impact of long term survivorship, finding community, and so much more!! Resources:Rebecca's Facebook: Rebecca ThomasEpic Experience: https://www.epicexperience.org/Follow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

Our guest this week is another hardcore Huntington Beach OG. A former pro snowboarder turned entrepreneur, he's had an impressive run across multiple industries over the past 20 years. From working as a physical therapist to repping for O'Neill Snow, his hustle never stopped. In 2004, after his cousin Brandon McGuinness (RIP) was diagnosed with Hodgkin's Lymphoma, he co-founded the F C Cancer Foundation—a 501(c)(3) nonprofit focused on early detection and prevention. As Executive Director and CEO, he's dedicated his life to pushing the Foundation's mission forward. We're stoked to hear about his journey, the legacy he's building, and the future he's shaping. Please welcome to the show, Mr. John "MUGS" McGuinness.

In this episode, Associate Blood editor Dr. Selina Luger leads a discussion with Drs. Courtney DiNardo, Eunice Wang, Andrew Wei and Gail Roboz about the advances in treatment options for Acute Myeloid Leukemia (AML). See the full How I Treat series on Acute Myeloid Leukemia in volume 145 issue 12 of Blood journal.

In this week's episode, we'll learn more about the effects of daratumumab maintenance on minimal residual disease in patients with newly diagnosed, transplant-eligible multiple myeloma; the role of neutrophils in the pathophysiology of myeloproliferative neoplasms; and a genome-wide association study that identified novel genetic loci associated with the risk of heavy menstrual bleeding.Featured ArticlesDaratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease resultsDefective neutrophil clearance in JAK2^V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24Genome-wide meta-analysis of heavy menstrual bleeding reveals 36 risk loci

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD The treatment landscape for relapsed/refractory (R/R) large B-cell lymphoma has significantly shifted, with CAR T-cell therapies now offering curative potential in the second-line setting. But these advances also raise important questions, like how to identify the right candidates and navigate logistical barriers to ensure timely, equitable access. Joining Dr. Charles Turck to explore these critical considerations is Dr. Saira Ahmed, Associate Professor in the Department of Lymphoma and Myeloma and the CAR T Program Director in the Department of Lymphoma and Myeloma at the MD Anderson Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD The treatment landscape for relapsed/refractory (R/R) large B-cell lymphoma has significantly shifted, with CAR T-cell therapies now offering curative potential in the second-line setting. But these advances also raise important questions, like how to identify the right candidates and navigate logistical barriers to ensure timely, equitable access. Joining Dr. Charles Turck to explore these critical considerations is Dr. Saira Ahmed, Associate Professor in the Department of Lymphoma and Myeloma and the CAR T Program Director in the Department of Lymphoma and Myeloma at the MD Anderson Cancer Center.

My guest today is Valerie David. NYC-based performer/playwright Valerie David wrote and performs her award-winning solo show, The Pink Hulk: One Woman's Journey to Find the Superhero Within, to inspire and empower others through the courage and inner strength she found to become a 3-time cancer survivor—Stage III Non-Hodgkin's Lymphoma, Stage II Breast Cancer, and Stage IV Metastatic Breast Cancer. Through medical advancements, Valerie currently has no evidence of disease. The Pink Hulk has been accepted into over 60 different play festivals and 25 different cities worldwide, including England, Sweden, Iceland, and Finland, garnering multiple awards. Valerie and her show have impacted audiences since its 2016 debut with its motto: NEVER GIVE UP HOPE! She received the President's Lifetime Achievement Award: Resilience in Action for her patient advocacy work from the Biden administration. Her second award-winning solo show, Baggage From BaghDAD: Becoming My Father's Daughter, is about her Middle Eastern Jewish family's true inspirational journey of being forced to flee from religious persecution during the 1941 “Farhud” pogrom in Baghdad. It is the story of Valerie's father and his family's struggle to transcend their harrowing past and build a new home in America. It celebrates the resiliency of the human spirit and finds humor, even in the darkest of times. In this episode we discuss cancer, self-advocacy, speaking your truth, healing and performance.Website: https://pinkhulkplay.com/LinkedIn - https://www.linkedin.com/in/valeriedavid/FB - https://www.facebook.com/pinkhulkplay/ https://www.facebook.com/valerie.david.96558/IG - https://www.instagram.com/valeriedavid_pinkhulkplay/YouTube - https://www.youtube.com/channel/UCyDPITlLi5AwO_1beXL2Ogw https://www.youtube.com/channel/UCXRTfJ7EdCBEjlhsZw3bI-wIn this episode you will learn:1. The power of laughter to help get through immense challenges.2. The importance of finding and using your voice to advocate for yourself .3. How empathy can help lead to opening your heart and understanding others. “I think what inspired me was the fact that I had two different cancers. So in breast cancer, according to the American Cancer Society, less than 1% of all men get breast cancer."- 00:07:35“If you're not in perpetual motion Then there's something wrong and I think that's the opposite because you need time to take a break You need time for yourself." - 00:25:46“I think it taught me to be in the now, in the present moment what can I do now and not to worry, look too much into the future because you don't, you're only in control of what you can do now.” 00:47:33

In this week's episode we'll learn more about enhanced transplant characteristics; targeting the JAK-STAT pathway with ruxolitinib in patients with adult-onset Still's disease and macrophage activation syndrome; and a pair of trials demonstrating lack of benefit for the anti-CD47 monoclonal antibody magrolimab in newly diagnosed acute myeloid leukemia.Featured ArticlesHeterogeneity of high-potency multilineage hematopoietic stem cells and identification of “Super” transplantabilityRuxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndromeMagrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 studyThe ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.Program Abstracts: POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCLECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCLCADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLLInMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FLSHR2554: Oral EZH2 Inhibitor in R/R PTCLSYRUS: AZD0486 Bispecific Antibody for R/R B-ALLPresenters:Max S. Topp, MDHead of Hematology and Clinical CAR-T Program LeadAssociated ProfessorMedinische Klinik und Poliklinkik IIUniversity of WurzburgWurzburg, GermanyPier Luigi Zinzani, MD, PhDProfessor of HematologyAlma Mater Studiorum- University of BolognaHead, “Seràgnoli” Institute of HematologyIRCCS Azienda Ospedaliero-Universitaria di BolognaDepartment of Medical and Surgical SciencesBologna University School of MedicineBologna, ItalyLink to full program:https://bit.ly/4obcJPI

In this week's episode, we'll learn about a JAK inhibitor to prevent complications of CD19-directed CAR T-cell therapy. In a phase 2 study, itacitinib was well tolerated and demonstrated promising reductions in the incidence of cytokine release syndrome and neurotoxicity. After that: investigators report direct interactions between ChAdOx1 and platelets under arterial shear conditions. Investigators say it's a novel biophysical mechanism that potentially contributes to post-vaccination arterial thrombosis. Finally, we explore lineage switch, an emerging form of acute leukemia relapse with dismal outcomes. It arises rapidly following antigen-targeted immunotherapy, highlighting the importance of advanced methods for detection and treatment.Featured Articles: Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 studyShear-dependent platelet aggregation by ChAdOx1 nCoV-19 vaccine: a novel biophysical mechanism for arterial thrombosisProject EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Dr. Pallawi Torka of Memorial Sloan Kettering Cancer Center joins to share highlights from ASCO and EHA 2025 on the evolving landscape of B-cell lymphomas, including Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma. She offers in-depth insights on the STARGLO study and its recent ODAC review, the POLARGO trial, a rare T-cell leukemia (T-LGL) study, and new data supporting nivolumab-AVD in frontline Hodgkin lymphoma. Additional discussion includes the inMIND trial for follicular lymphoma, the growing role of ctDNA in managing DLBCL, advances in CAR-T cell therapy for CNS lymphoma, and how she is adapting treatment strategies based on favorable vs. unfavorable disease features. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Meet Nikki, whose bout with mono when she was younger ultimately led to a diagnosis of Hodgkin's Lymphoma as an adult.  But Nikki is one of the lucky ones - her case was not only treatable, but curable.     #unroutineinspiration

Welcome to this episode of The Oncology Brothers! Drs. Rahul and Rohit Gosain dived into the complexities of relapsed refractory diffuse large B-cell lymphoma (DLBCL) with their new series focused on challenging real-life cases. In this episode, we are joined by esteemed guests Dr. Carla Casulo from Wilmot Cancer Center and Dr. Tara Graff from Mission Cancer and Blood Center. Together, we explored the current standard of care, including R-CHOP and the role of bi-specific antibodies like epcoritamab and glofitimab. Key topics covered included: • When to use bi-specific antibodies and how to manage side effects • The importance of MRD monitoring in treatment decisions • Insights on patient management in community oncology settings • The evolving landscape of treatment options for DLBCL, including CAR-T therapy and clinical trials We also discuss practical considerations for community oncologists, including the management of cytokine release syndrome (CRS) and the role of immunoglobulin therapy in patients with low IgG levels. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable insights and expert opinions. YouTube: https://youtu.be/05ieIyAIx_8 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and share your thoughts in the comments! Let us know if there are specific scenarios you'd like us to cover in future episodes.

In this week's episode we'll learn more about the use of ruxolitinib plus dexamethasone to treat newly diagnosed patients with adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors as a potential new class of therapies for sickle cell disease and other beta-globinopathies; and insights into clinical characteristics of patients with von Willebrand factor levels that are lower than normal but higher than those typically used to diagnose von Willebrand disease.Featured Articles:Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in ChinaNovel, potent, and orally bioavailable LSD1 inhibitors induce fetal hemoglobin synthesis in a sickle cell disease mouse modelClinical phenotype and pathophysiological mechanisms underlying qualitative low VWF

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NAW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 6, 2026.Expanding the Bispecific Option Across Hematologic Cancers: Guidance for the Community on Collaborative Care and Accessing Innovative Immunotherapy for Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NAW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 6, 2026.Expanding the Bispecific Option Across Hematologic Cancers: Guidance for the Community on Collaborative Care and Accessing Innovative Immunotherapy for Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NAW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 6, 2026.Expanding the Bispecific Option Across Hematologic Cancers: Guidance for the Community on Collaborative Care and Accessing Innovative Immunotherapy for Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NAW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 6, 2026.Expanding the Bispecific Option Across Hematologic Cancers: Guidance for the Community on Collaborative Care and Accessing Innovative Immunotherapy for Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain dive deep into the world of diffuse large B-cell lymphoma (DLBCL), one of the most aggressive yet potentially curable lymphomas. We are joined by Dr. John Leonard, a renowned lymphoma expert from NYU Langone Cancer Center, who shares his insights on the latest data and evolving treatment landscape for DLBCL. Episode Highlights: •⁠  ⁠Understanding the initial workup for DLBCL, including the role of PET-CT and bone marrow biopsies. •⁠  ⁠The use of RCHOP and the emerging Pola-R-CHP regimen in Stage 1 and Stage 2 settings. •⁠  ⁠Discussion on the treatment options for Stage 3 and Stage 4 disease, including the impact of polatuzumab. •⁠  ⁠Insights into managing relapsed/refractory disease and the role of CAR-T therapy. •⁠  ⁠The potential shift towards outpatient CAR-T treatments and the nuances between different CAR-T options. •⁠  ⁠Exploring bispecific antibodies and their applications in treatment sequencing. YouTube: https://youtu.be/raGkPnUs9XM Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we unpack the complexities of DLBCL treatment and share valuable clinical pearls for community settings. Don't forget to subscribe for more episodes on challenging cases and the latest in oncology!

In this episode, Associate Editor Dr. Philippe Armand discusses the Review Series on mantle cell lymphoma with author Dr. Christine Ryan. Both were authors of "Frontline management of mantle cell lymphoma", and discuss shifts in treatments and new research.Find the full review series in Volume 145 Issue 7 of Blood: "Review series on mantle cell lymphoma: sands shifting in the darkness"

Today, on Karl and Crew, we kicked off the week with discussions about a cancer patient ministry with Phil Zielke and how to make the most of a screen-free summer with your kids, with Arlene Pellicane. First, Phil Zielke joined us to share his testimony of how he drew near to God when he was diagnosed with Stage 4B Hodgkin’s Lymphoma, and then how God placed it on his heart to start a ministry that serves cancer patients. Phil’s Friends is a ministry that provides Christ-centered support and hope to those affected by cancer. Then we had Arlene Pellicane join us to talk about the importance of parents connecting with their children by limiting their screen time. Arlene is a speaker, author, and host of the Happy Home podcast. She is also a marriage and parenting expert. Arlene has also authored several books, including “Screen Kids.” We then discussed our need for God’s grace. We were born into sin, so it is in our nature to be sinful, but when we are born again through Christ, we are renewed by God’s grace. Romans 7:18-25 affirms this, as Paul tells us that sin dwells within us and affects how we move and think without God. Only God can deliver us from sin through Jesus Christ. We also heard updates from Karl, who was broadcasting remotely from the Maranatha Bible Missionary Conference, Vacation and Retreat Center. Dr. Josh Stephens joined Karl to discuss the sovereignty and providence of God as shown throughout the book of Ruth. Dr. Stephens is the Lead Pastor of Cape Bible Church in Missouri and is also the founder and executive director of the Biblical Counseling Alliance. You can hear the highlights of today's program on the Karl and Crew Showcast. If you're looking to hear a particular segment from the show, look at the following time stamps: Gospel (Need for God) [ 05:55-17:30 ] Phil Zielke Interview (Phil's Friends Ministry) [ 44:25-55:18 ] Arlene Pellicane Interview [ 55:28-01:06:34 ] Dr. Josh Stephens (Book of Ruth breakdown) [ 30:50-43:50 ]Donate to Moody Radio: http://moodyradio.org/donateto/morningshowSee omnystudio.com/listener for privacy information.

Today, on Karl and Crew, we kicked off the week with discussions about a cancer patient ministry with Phil Zielke and how to make the most of a screen-free summer with your kids, with Arlene Pellicane. First, Phil Zielke joined us to share his testimony of how he drew near to God when he was diagnosed with Stage 4B Hodgkin’s Lymphoma, and then how God placed it on his heart to start a ministry that serves cancer patients. Phil’s Friends is a ministry that provides Christ-centered support and hope to those affected by cancer. Then we had Arlene Pellicane join us to talk about the importance of parents connecting with their children by limiting their screen time. Arlene is a speaker, author, and host of the Happy Home podcast. She is also a marriage and parenting expert. Arlene has also authored several books, including “Screen Kids.” We then discussed our need for God’s grace. We were born into sin, so it is in our nature to be sinful, but when we are born again through Christ, we are renewed by God’s grace. Romans 7:18-25 affirms this, as Paul tells us that sin dwells within us and affects how we move and think without God. Only God can deliver us from sin through Jesus Christ. We also heard updates from Karl, who was broadcasting remotely from the Maranatha Bible Missionary Conference, Vacation and Retreat Center. Dr. Josh Stephens joined Karl to discuss the sovereignty and providence of God as shown throughout the book of Ruth. Dr. Stephens is the Lead Pastor of Cape Bible Church in Missouri and is also the founder and executive director of the Biblical Counseling Alliance. You can hear the highlights of today's program on the Karl and Crew Showcast. If you're looking to hear a particular segment from the show, look at the following time stamps: Gospel (Need for God) [ 05:55-17:30 ] Phil Zielke Interview (Phil's Friends Ministry) [ 44:25-55:18 ] Arlene Pellicane Interview [ 55:28-01:06:34 ] Dr. Josh Stephens (Book of Ruth breakdown) [ 30:50-43:50 ]Donate to Moody Radio: http://moodyradio.org/donateto/morningshowSee omnystudio.com/listener for privacy information.

Today, on Karl and Crew, we kicked off the week with discussions about a cancer patient ministry with Phil Zielke and how to make the most of a screen-free summer with your kids, with Arlene Pellicane. First, Phil Zielke joined us to share his testimony of how he drew near to God when he was diagnosed with Stage 4B Hodgkin’s Lymphoma, and then how God placed it on his heart to start a ministry that serves cancer patients. Phil’s Friends is a ministry that provides Christ-centered support and hope to those affected by cancer. Then we had Arlene Pellicane join us to talk about the importance of parents connecting with their children by limiting their screen time. Arlene is a speaker, author, and host of the Happy Home podcast. She is also a marriage and parenting expert. Arlene has also authored several books, including “Screen Kids.” We then discussed our need for God’s grace. We were born into sin, so it is in our nature to be sinful, but when we are born again through Christ, we are renewed by God’s grace. Romans 7:18-25 affirms this, as Paul tells us that sin dwells within us and affects how we move and think without God. Only God can deliver us from sin through Jesus Christ. We also heard updates from Karl, who was broadcasting remotely from the Maranatha Bible Missionary Conference, Vacation and Retreat Center. Dr. Josh Stephens joined Karl to discuss the sovereignty and providence of God as shown throughout the book of Ruth. Dr. Stephens is the Lead Pastor of Cape Bible Church in Missouri and is also the founder and executive director of the Biblical Counseling Alliance. You can hear the highlights of today's program on the Karl and Crew Showcast. If you're looking to hear a particular segment from the show, look at the following time stamps: Gospel (Need for God) [ 05:55-17:30 ] Phil Zielke Interview (Phil's Friends Ministry) [ 44:25-55:18 ] Arlene Pellicane Interview [ 55:28-01:06:34 ] Dr. Josh Stephens (Book of Ruth breakdown) [ 30:50-43:50 ]Donate to Moody Radio: http://moodyradio.org/donateto/morningshowSee omnystudio.com/listener for privacy information.

Today, on Karl and Crew, we kicked off the week with discussions about a cancer patient ministry with Phil Zielke and how to make the most of a screen-free summer with your kids, with Arlene Pellicane. First, Phil Zielke joined us to share his testimony of how he drew near to God when he was diagnosed with Stage 4B Hodgkin’s Lymphoma, and then how God placed it on his heart to start a ministry that serves cancer patients. Phil’s Friends is a ministry that provides Christ-centered support and hope to those affected by cancer. Then we had Arlene Pellicane join us to talk about the importance of parents connecting with their children by limiting their screen time. Arlene is a speaker, author, and host of the Happy Home podcast. She is also a marriage and parenting expert. Arlene has also authored several books, including “Screen Kids.” We then discussed our need for God’s grace. We were born into sin, so it is in our nature to be sinful, but when we are born again through Christ, we are renewed by God’s grace. Romans 7:18-25 affirms this, as Paul tells us that sin dwells within us and affects how we move and think without God. Only God can deliver us from sin through Jesus Christ. We also heard updates from Karl, who was broadcasting remotely from the Maranatha Bible Missionary Conference, Vacation and Retreat Center. Dr. Josh Stephens joined Karl to discuss the sovereignty and providence of God as shown throughout the book of Ruth. Dr. Stephens is the Lead Pastor of Cape Bible Church in Missouri and is also the founder and executive director of the Biblical Counseling Alliance. You can hear the highlights of today's program on the Karl and Crew Showcast. If you're looking to hear a particular segment from the show, look at the following time stamps: Gospel (Need for God) [ 05:55-17:30 ] Phil Zielke Interview (Phil's Friends Ministry) [ 44:25-55:18 ] Arlene Pellicane Interview [ 55:28-01:06:34 ] Dr. Josh Stephens (Book of Ruth breakdown) [ 30:50-43:50 ]Donate to Moody Radio: http://moodyradio.org/donateto/morningshowSee omnystudio.com/listener for privacy information.

Today, on Karl and Crew, we kicked off the week with discussions about a cancer patient ministry with Phil Zielke and how to make the most of a screen-free summer with your kids, with Arlene Pellicane. First, Phil Zielke joined us to share his testimony of how he drew near to God when he was diagnosed with Stage 4B Hodgkin’s Lymphoma, and then how God placed it on his heart to start a ministry that serves cancer patients. Phil’s Friends is a ministry that provides Christ-centered support and hope to those affected by cancer. Then we had Arlene Pellicane join us to talk about the importance of parents connecting with their children by limiting their screen time. Arlene is a speaker, author, and host of the Happy Home podcast. She is also a marriage and parenting expert. Arlene has also authored several books, including “Screen Kids.” We then discussed our need for God’s grace. We were born into sin, so it is in our nature to be sinful, but when we are born again through Christ, we are renewed by God’s grace. Romans 7:18-25 affirms this, as Paul tells us that sin dwells within us and affects how we move and think without God. Only God can deliver us from sin through Jesus Christ. We also heard updates from Karl, who was broadcasting remotely from the Maranatha Bible Missionary Conference, Vacation and Retreat Center. Dr. Josh Stephens joined Karl to discuss the sovereignty and providence of God as shown throughout the book of Ruth. Dr. Stephens is the Lead Pastor of Cape Bible Church in Missouri and is also the founder and executive director of the Biblical Counseling Alliance. You can hear the highlights of today's program on the Karl and Crew Showcast. If you're looking to hear a particular segment from the show, look at the following time stamps: Gospel (Need for God) [ 05:55-17:30 ] Phil Zielke Interview (Phil's Friends Ministry) [ 44:25-55:18 ] Arlene Pellicane Interview [ 55:28-01:06:34 ] Dr. Josh Stephens (Book of Ruth breakdown) [ 30:50-43:50 ]Donate to Moody Radio: http://moodyradio.org/donateto/morningshowSee omnystudio.com/listener for privacy information.

In this week's episode, we'll learn about rapid, high-sensitivity diagnostic assays for TTP, or thrombotic thrombocytopenic purpura, that can reduce unnecessary treatments. After that: enhancing PD-1 blockade in relapsed/refractory extranodal NK/T-cell lymphoma. In a single-arm, phase 2 study, combined CD38 and PD-1 inhibition demonstrated durable responses and manageable safety. Finally, a lymphoma horror story with a happy ending. CREBBP mutations create a zombie enzyme that competes with its wild-type counterparts. By enforcing CD40 signaling, a bispecific antibody overcomes this effect and induces lymphoma cell death.Featured Articles:Rapid ADAMTS13 activity assays for thrombotic thrombocytopenic purpura: a systematic review and meta-analysisEfficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphomaBlunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement

Heather Lino's then 3 year old son James was given a double whammy in 2020 when he was first diagnosed with T Cell Acute Lymphoblastic Lymphoma in July, and then roughly one month into his treatment he was diagnosed with a Chromosomal disorder known as Ring 14 Syndrome. This disorder affects 200-250 people around the world. This affliction causes seizures and intellectual disabilities and can have other problems associated with it as well. James is now 8 years old and is living his best life possible. 

Originally aired in 2023, Molly Jacobson interviews Dr. Kim Agnew about the groundbreaking trials of Monepantel, a sheep dewormer repurposed as a potential treatment for canine lymphoma. Discover the science behind this innovative therapy, its potential to stabilize lymphoma, and how it compares to traditional treatments like chemotherapy and prednisone.  Key Topics:  What is Monepantel, and how was it discovered?  The mechanism behind Monepantel's ability to target cancer cells.  Early trial results: Quality of life and stability for dogs with B-cell lymphoma.  How Monepantel compares to prednisone and chemotherapy.  Insights into ongoing and future clinical trials.  How dog lovers can participate in studies.  Your Voice Matters!   If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question.   Related Videos:  https://www.youtube.com/watch?v=_92w6TTXM5c   https://www.youtube.com/watch?v=uAZrPM1X8ww   Related Links:  PharmAust Dog Lymphoma Clinical Trial: https://www.pharmaust.com/petdogtrial/  Chapters:  00:00 Introduction  00:30 Meet Dr. Kim Agnew and Monepantel Overview  01:15 The Origin of Monepantel: From Dewormer to Cancer Fighter  03:30 How Monepantel Targets Cancer Cells  07:00 Insights on Clinical Trials for Canine Lymphoma  09:30 Benefits of Monepantel: A Daily Pill for Dogs  12:00 Comparing Monepantel to Chemotherapy and Prednisone  14:45 Early Trial Results: Stabilizing Lymphoma in Dogs  18:30 Why Lymphoma Was Chosen for Trials  20:00 Potential for Treating Other Cancers in Dogs  23:15 How to Enroll Dogs in Clinical Trials  26:45 Side Effects and Safety of Monepantel  31:00 Future Trials and Research Goals  34:30 Closing Thoughts and Resources  33:55 Closing Remarks and Resources    Get to know Kim Agnew, BVSc: https://www.dogcancer.com/people/kim-agnew-bvsc/     For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/   Learn more about your ad choices. Visit megaphone.fm/adchoices

In a heartfelt conversation, Def Leppard guitarist Vivian Campbell reveals his remarkable path to beating cancer through a successful bone marrow transplant. He discusses his 13-year battle with Hodgkin's Lymphoma, the emotional impact of finding a perfect donor match, and his unwavering determination to keep performing throughout treatment. Campbell also shares updates on Def Leppard's upcoming album, his side project Last in Line, and his newfound passion for rally racing. Also on the podcast, from writing 'New York Groove' on a flight to NYC to seeing The Beatles adopt his tailor recommendations, Russ Ballard opens up about his remarkable 60-year career crafting hits for rock's biggest names. He reveals the origins of classics like 'Since You've Been Gone' and 'God Gave Rock and Roll to You,' while discussing his latest double album and philosophy that keeping active in music helps maintain youthful energy.  Catch Eddie Trunk every M-F from 3:00-5:00pm ET on Trunk Nation on SiriusXM Faction Talk Channel 103.And don't forget to follow Eddie on Twitter and Instagram!Follow the link to get your free 3-month trial of SiriusXM: http://siriusxm.com/eddietrunk Find all episodes of Trunk Nation: https://siriusxm.com/trunknation

Mike is out of town, so Jim brought in one of Third Street Barbell's most consistent and inspirational members, Josh Hajar.Josh is an emergency department nurse who faced a harrowing fight with non-Hodgkin's Lymphoma, and then suffered an injury that set back his recovery and fitness goals. When he arrived at Third Street, he was finally ready to execute a winning game plan for losing weight and getting stronger. Building on the advice he received when he first received his cancer diagnosis to “Be Positive,” Josh sets a strong example in and out of the gym.Join our Discord for free at goodcompanydiscord.com!Check out our gym (Third Street Barbell) at ThirdStreetBarbell.com https://www.thirdstreetbarbell.com/ and subscribe for updates about our apparel line at goodcompanyapparel.com https://3sb.co/! Local memberships and international fresh fits! Get early access to our NEXT DROP!Check out our podcast website: 50percentfacts.com https://www.50percentfacts.com/50% Facts is a Spreaker Prime podcast on OCN – the Obscure Celebrity Network.____Hosted by Mike Farr (@silentmikke) https://www.instagram.com/silentmikke/ and Jim McDonald (@thejimmcd). https://www.instagram.com/thejimmcd/Produced by Jim McDonaldProduction assistance by Sam McDonald and Sebastian Brambila.Theme by Aaron Moore. Show art by Joseph Manzo (@jmanzo523)Become a supporter of this podcast: https://www.spreaker.com/podcast/50-facts-with-silent-mike-jim-mcd--5538735/support.